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nsulin-like growth factors elicit many responses through
activation of phosphoinositide 3-OH kinase (PI3K). The
tuberous sclerosis complex (
 
TSC1-2
 
) suppresses cell growth
by negatively regulating a protein kinase, p70S6K (S6K1),
which generally requires PI3K signals for its activation.
Here, we show that 
 
TSC1-2
 
 is required for insulin signaling
to PI3K. 
 
TSC1-2
 
 maintains insulin signaling to PI3K by
I
 
restraining the activity of S6K, which when activated inacti-
vates insulin receptor substrate (IRS) function, via repression
of IRS-1 gene expression and via direct phosphorylation of
IRS-1. Our results argue that the low malignant potential of
tumors arising from 
 
TSC1-2
 
 dysfunction may be explained
by the failure of TSC mutant cells to activate PI3K and its
downstream effectors.
 
Introduction
 
The signal transduction mechanisms operating downstream
of insulin receptor ligation have highlighted the importance
both of the receptor tyrosine kinase substrates (insulin recep-
tor substrates, IRS-1 and IRS-2) and the lipid kinase phos-
phoinositide 3-OH kinase (PI3K; Saltiel, 2001; Saltiel and
Kahn, 2001; Cantley, 2002; White, 2002). Activation of
PI3K occurs via recruitment to IRS proteins, and is critical
in generating many of the cell’s responses to insulin (Shepherd
et al., 1998). The insulin–PI3K pathway also plays a conserved
role in regulating cell and organism size. Mice deficient in
effectors of PI3K, PDK1 and S6K1, exhibit growth defects
(Shima et al., 1998; Lawlor et al., 2002), whereas activation
of PI3K leads to increases in cell and organ growth (Leevers
et al., 1996; Crackower et al., 2002; Shioi et al., 2002). The
growth response to insulin-like growth factors involves the
S6 kinases and leads to increased translation of 5
 
 
 
-terminal
oligopyrimidine track mRNAs (Jefferies et al., 1997), many
of which encode ribosomal proteins. By increasing ribosome
biogenesis, activation of S6K is thought to lead to an increase
in protein synthesis (Volarevic and Thomas, 2001). Two
S6K genes, 
 
S6K1
 
 and 
 
S6K2
 
, together encode four kinase
isoforms, three of which are present in the nucleus (Reinhard
et al., 1992; Gout et al., 1998). Two signaling pathways
have been shown to positively regulate S6K: the insulin–
PI3K pathway (Reif et al., 1997; Martin et al., 2001) and a
nutrient pathway involving the mammalian target of rapa-
mycin (mTOR; Brown et al., 1995; Park et al., 2002). A ge-
netic regulator of S6K1 activity has also been identified—
the tumor suppressor tuberous sclerosis complex (TSC1-2),
a complex of the 
 
TSC1
 
 and 
 
TSC2
 
 gene products, hamartin
and tuberin (van Slegtenhorst et al., 1998). Inactivation of
TSC1-2 leads to constitutive S6K1 activity (Jaeschke et al.,
2002; Kwiatkowski et al., 2002) and growth in 
 
Drosophila
 
(Ito and Rubin, 1999; Gao and Pan, 2001; Potter et al.,
2001; Tapon et al., 2001). An inhibitory target of TSC1-2
action has been identified as Rheb, a small GTPase (Garami
et al., 2003; Saucedo et al., 2003; Stocker et al., 2003; Y.
Zhang et al., 2003) with Rheb overexpression resulting in
activation of S6K (for review see Li et al., 2004).
A key unresolved question is how S6K activation and
growth stimulated by insulin-like growth factors is appropri-
ately coordinated with the other responses downstream of
PI3K that include cell proliferation and survival. Negative
 
L.S. Harrington and G.M. Findlay contributed equally to this paper.
Address correspondence to Richard F. Lamb, Cancer Research UK
Centre for Cell and Molecular Biology, The Institute of Cancer Research,
237 Fulham Rd., London SW3 6JB, England, UK. Tel.: (44) 207-970-
6096. Fax: (44) 207-352-5630. email: Richard.Lamb@icr.ac.uk
Key words: TSC1-2; PI3K; IRS proteins; S6K; insulin
 
Abbreviations used in this paper: IRS, insulin receptor substrate; MEF,
mouse embryo fibroblast; mTOR, mammalian target of rapamycin;
PI3K, phosphoinositide 3-OH kinase; PIP3, phosphatidylinositol 3,4,5-
trisphosphate; PTB, phosphotyrosine-binding domain; siRNA, small
interfering RNA; TSC, tuberous sclerosis complex. 
214 The Journal of Cell Biology 
 
|
 
 
 
Volume 166, Number 2, 2004
 
feedback loops relating a downstream response of insulin–
PI3K signaling to the overall level of pathway activation
would be a potential means of accomplishing this type of co-
ordination. Here, we show that by suppressing such a nega-
tive feedback loop, 
 
TSC1-2
 
 is a key positive regulator of
PI3K signaling. 
 
TSC1-2
 
 promotes PI3K signaling by sup-
pressing S6K, thereby preventing S6K-dependent inactiva-
tion of IRS-1 and IRS-2. As a result of IRS inactivation,
 
TSC2
 
-deficient cells exhibit a profound defect in PI3K sig-
naling and fail to activate the serine-threonine kinase PKB
or respond to the migration and pro-survival activities of
IGF-1. We show that for IRS-1, the inactivation is exerted
through S6K-dependent suppression of gene transcription
and by direct phosphorylation by S6K1 in a region criti-
cal for IRS-1 adaptor function. We suggest that although
 
TSC1-2
 
 loss of function promotes hamartomatous growth
in TSC, a failure to activate insulin–PI3K signaling may ex-
plain the low malignant potential of such tumors.
 
Results
 
TSC1-2 specifically regulates insulin signaling to PI3K
 
Insulin-stimulated activation of the PI3K-regulated serine-
threonine kinase PKB (also known as AKT) is defective in
cells deficient in 
 
TSC2
 
 (Jaeschke et al., 2002) or 
 
TSC1
 
(Kwiatkowski et al., 2002). To determine whether there is
a specific impairment of insulin-like growth factor signal-
ing, we assayed PKB activity after stimulation of cells with
insulin, IGF-1, or EGF. In control 
 
TSC2
 
 
 
/
 
 
 
 mouse em-
bryo fibroblasts (MEFs) or 
 
TSC2
 
 
 
/
 
 
 
 MEFs in which wild-
type 
 
TSC2
 
 has been reintroduced (Jaeschke et al., 2002),
PKB is activated by insulin, IGF-1, and EGF (Fig. 1 A). In
contrast, in 
 
TSC2
 
 
 
/
 
 
 
 MEFs or 
 
TSC2
 
 
 
/
 
 
 
 MEFs in which a
pathogenic 
 
TSC2
 
 mutant is reintroduced, PKB is activated
strongly only by EGF. Similarly, a downstream effector of
PKB, GSK3
 
 
 
/
 
 
 
, is robustly phosphorylated in response to
stimulation by all three growth factors in control MEFs,
but only strongly by EGF in 
 
TSC2
 
 
 
/
 
 
 
 MEFs (Fig. 1 B).
Because PKB activation generally requires PI3K activation
and the production of phosphatidylinositol 3,4,5-trisphos-
phate (PIP3) at the membrane (Cantley, 2002), we assayed
PI3K activity and measured levels of PIP3 after stimulation
with IGF-1 or EGF. 
 
TSC2
 
 
 
/
 
 
 
 MEFs neither activate PI3K
(Fig. 1 C) nor elevate levels of PIP3 in response to IGF-1
stimulation (Fig. 1 D), whereas PIP3 generated after stimu-
lation with EGF is similar to that of control 
 
TSC2
 
-express-
ing MEFs (Fig. 1 D). Thus, the failure to activate PKB after
stimulation with insulin or IGF-1 in 
 
TSC2
 
-deficient cells is
due to a general failure to activate PI3K and generate its
lipid product, PIP3.
 
TSC1-2
 
 regulates 
 
IRS-1
 
 mRNA via S6K
 
The basis of the insulin signaling defect in cells lacking
 
TSC2
 
 could be either at the level of expression of the insu-
lin/IGF-1 receptors or IRS proteins, or at the level of their
activation. Therefore, we performed a microarray analy-
sis of gene expression differences between 
 
TSC2
 
 
 
/
 
 
 
 and
 
TSC2
 
 
 
/
 
 
 
 MEFs, which shows that the level of the 
 
IRS-1
 
mRNA is significantly reduced in 
 
TSC2
 
 
 
/
 
 
 
 MEFs (Fig. 2
A). To confirm this result, we analyzed 
 
IRS-1
 
 mRNA. 
 
IRS-1
 
mRNA abundance is significantly reduced in 
 
TSC2
 
 
 
/
 
 
 
MEFs (Fig. 2 B). Importantly, this reduction is fully re-
versed by stable retroviral introduction of wild-type 
 
TSC2
 
(Fig. 2 B). Interestingly, the level of 
 
IRS-2
 
 mRNA is unaf-
fected by the absence of functional 
 
TSC2
 
. A similar result
is obtained comparing the levels of IRS-1 protein in these
cells by Western blotting, whereas the levels of IRS-2 pro-
tein or of the insulin or IGF receptors is unaffected by
 
TSC2
 
 expression (Fig. 2 C). Thus, 
 
IRS-1
 
 expression is
maintained by the presence of functional 
 
TSC2
 
.
IRS-1 protein levels have previously been shown to be
rapamycin sensitive (Haruta et al., 2000). Because mTOR/
Figure 1. PI3K activation by insulin-like 
growth factors is dependent on functional 
TSC2. (A) PKB activation in cells express-
ing or lacking functional TSC2. PKB 
activation in isogenic TSC2
 / , TSC2
 /  
MEFs, and TSC2
 /  MEF lines in which 
wild-type ( /  ( WT)) or a pathogenic 
mutant TSC2 ( /  ( N1643K)) has 
been reintroduced were starved and 
stimulated with the indicated growth 
factors for 10 min. The ability of insulin, 
IGF-1, and EGF to activate PKB is dem-
onstrated by phosphorylation of Ser-473 
(S473-P). (B) Phosphorylation of GSK3 / , 
at GSK3  Ser-21 (top) and GSK3  Ser-9 
(middle) after insulin, IGF-1, or EGF stim-
ulation. Bottom: total GSK3 / . (C) PI3K 
activity in TSC2
 /  or TSC2
 /  MEFs, or 
TSC2
 /  MEFs reconstituted with wild-
type TSC2 ( WT) or a disease-causing 
mutant TSC2 ( N1643K) after stimulation 
with IGF-1. Results are expressed as values 
relative to unstimulated controls. (D) PIP3 
levels in TSC2
 /  or TSC2
 /  MEFs, or 
TSC2
 /  MEFs reconstituted with wild-type TSC2 ( WT) or a disease-causing mutant TSC2 ( N1643K) after stimulation with IGF-1 or EGF. 
The results (means and SD of triplicate determinations) are expressed relative to control unstimulated cells. 
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S6K signaling is hyperactivated in 
 
TSC2-deficient cells
(Jaeschke et al., 2002), we sought to examine the effect of
rapamycin on IRS-1 mRNA abundance. Rapamycin treat-
ment of TSC2
 /  MEFs relieves the suppression of IRS-1
mRNA abundance after  24 h of treatment (Fig. 3 A).
This restoration of IRS-1 mRNA abundance by sustained
rapamycin treatment is reversed by actinomycin D (Fig. 3,
B and C), indicating that mTOR/S6K1 signaling likely re-
duces IRS-1 mRNA abundance primarily at the level of
gene transcription.
Next, we asked whether the suppression of IRS-1 mRNA
was mediated by either S6K1 or S6K2, both of which are ra-
pamycin-sensitive kinases, using a small interfering RNA
(siRNA) approach. A near complete knock-down of S6K1
and a 70–80% knock-down of S6K2 is observed (Fig. 3 D).
Suppression of either S6K1 or S6K2 mimics the effect of ra-
pamycin treatment and restores IRS-1 mRNA to a level ap-
proaching that of TSC2
 /  MEFs (Fig. 3, E and F). We
conclude that the suppression of IRS-1 mRNA we observe in
TSC2-deficient cells is mediated by both forms of S6K—
S6K1 and S6K2.
TSC1-2 promotes insulin signaling by inhibiting S6K 
action on IRS-1
IRS-1 and IRS-2 proteins extracted from TSC2
 /  MEFs
exhibit reduced migration on SDS-PAGE gels (Fig. 2 C).
Treatment of IRS-1 immunoprecipitates with  -phos-
phatase indicates that the reduced migration of IRS-1 in
Figure 2. IRS-1 mRNA and protein expression is dependent on TSC2. 
(A) Microarray analysis of TSC2
 /  and TSC2
 /  MEFs. IRS-1 mRNA 
is more abundant in TSC2
 /  MEFs (green) compared with TSC2
 /  
MEFs (red). (B) Northern blotting of IRS-1 (top) or IRS-2 (middle) 
mRNAs in isogenic TSC2
 / , TSC2
 /  MEFs, and a TSC2
 /  MEF line 
in which wild-type TSC2 has been reintroduced ( /   WT). 
Aliquots of these samples were run on a separate gel and probed for 
 -actin as a control for RNA content (bottom). White line indicates 
that intervening lanes have been removed. (C) IRS-1 (first panel), IRS-2 
(second panel), InR (third panel), and IGF1-R (fourth panel) protein 
levels in TSC2
 / , TSC2
 / , and a TSC2
 /  MEF line in which wild-
type TSC2 has been reintroduced ( /   WT). A blot was reprobed 
for ERK1/2 as a control for protein loading (bottom panel).
Figure 3. Inhibition of S6K restores IRS-1 mRNA. (A) IRS-1 mRNA 
levels (top) in serum-starved TSC2
 /  or TSC2
 /  MEFs in untreated 
cells or after the addition of 20 nM rapamycin for various times. The 
blot was reprobed for  -actin as a control for mRNA loading (bottom). 
White line indicates that intervening lanes have been removed. (B) 
IRS-1 mRNA levels (top) in TSC2
 /  MEFs treated with 20 nM 
rapamycin alone, or in the presence of 10  g/ml actinomycin D for 
the final 10 h of a 24-h treatment. The blot was reprobed for  -actin 
as a control for mRNA loading (bottom). (C) Quantitative RT-PCR 
analysis of untreated, rapamycin-treated, and rapamycin plus actino-
mycin D–treated TSC2
 /  MEFs. Left,  -actin; right, IRS-1. A single 
graph from triplicate determinations showing identical results is 
shown. (D) RNAi-mediated inhibition of S6K1 and S6K2. Western 
blotting of extracts from TSC2
 /  or TSC2
 /  MEFs transfected with a 
combination of scrambled siRNAs (C) or S6K1, S6K2, or S6K1 plus 
S6K2 siRNAs. Top, S6K1; middle, S6K2; bottom, anti-pS6 (Ser240/
244). Where indicated, cells were stimulated for 10 min with insulin 
or treated with 20 nM rapamycin for 1 h. (E) IRS-1 mRNA levels in 
TSC2
 /  MEFs or TSC2
 /  MEFs transfected with a combination of 
S6K1 and S6K2 scrambled siRNAs (C), S6K1, or S6K2 siRNAs, or 
treated for 24 h with 20 nM rapamycin. Top, IRS-1 mRNA; The 
blot was also reprobed for  -actin as a control for mRNA loading 
(bottom). (F) Quantitative RT-PCR analysis of untreated TSC2
 / , 
TSC2
 / , or TSC2
 /  treated with 20 nM rapamycin or RNAi to S6K1 
or S6K2. Left,  -actin; right, IRS-1. A single graph from triplicate 
determinations showing identical results is shown.216 The Journal of Cell Biology | Volume 166, Number 2, 2004
TSC2
 /  MEFs is due to differences in phosphorylation,
with the protein exhibiting a larger change in mobility than
IRS-1 from TSC2
 /  MEFs after phosphatase treatment
(Fig. 4 A). To determine if this change in IRS-1 phosphor-
ylation is caused by mTOR/S6K signaling, we treated
TSC2
 /  or TSC
 /  MEFs for various times with rapamycin
and examined IRS-1 and IRS-2 protein levels. Both IRS-1
and IRS-2 migrate as slower species in TSC2-deficient cells.
After the addition of rapamycin to TSC2
 /  MEFs for 1 h,
both IRS-1 and IRS-2 migrate as faster migrating species
with no increase in protein levels. However, after 24 h treat-
ment with rapamycin, the migration and level of IRS-1 pro-
tein in TSC2
 /  MEFs is similar to that of untreated
TSC2
 /  MEFs (Fig. 4 B). In contrast, the level of IRS-2 is
largely unaffected by rapamycin treatment in either TSC2
 / 
or TSC2
 /  MEFs. PKB activation in TSC2
 /  MEFs is
partially restored after 1 h of rapamycin treatment, and is
fully restored after 24 h of treatment (Fig. 4 C). Consistent
with the rescue of PKB activation, the elevation of PIP3 af-
ter IGF-1 stimulation of TSC2
 /  MEFs pretreated with ra-
pamycin for 24 h is similar to that produced in stimulated
TSC2
 /  MEFs (Fig. 4 D).
To examine whether the rescuing effect of rapamycin
upon insulin signaling is mediated via effects on IRS-1 or
IRS-2, we again used siRNAs. The partial rescue of PKB ac-
tivation we observe with 1 h of rapamycin treatment is di-
minished by suppression of either IRS-1 or, to a lesser ex-
tent, IRS-2, with a more pronounced effect observed when
both proteins are suppressed (Fig. 4 E). To determine
whether perturbation of IRS function is the critical lesion
responsible for diminished insulin signaling in TSC2
 / 
MEFs, we then asked whether insulin signaling could be res-
cued in TSC2
 /  MEFs after overexpression of IRS-1 or
IRS-2. We find that overexpression of either IRS-1 or IRS-2
results in an increase in PKB activation, which when com-
bined with short-term inhibition of mTOR/S6K signaling
using rapamycin leads to a phenocopy of the effect of sus-
tained (24 h) treatment with rapamycin (Fig. 4 F).
Then, we asked whether the enhanced effect on signaling
we observe after rapamycin is due to inhibition of S6K, us-
ing siRNAs. The results indicate that suppression of either
S6K1 or S6K2 in TSC2
 /  MEFs leads to an increase in
PKB activation, with a larger increase elicited by suppression
of S6K1 (Fig. 4 G). Suppression of either kinase leads to an
equivalent increase in the level of IRS-1 protein, with no ef-
fect on IRS-2. Together, these results show that the reduced
insulin signaling we observed in TSC2
 /  MEFs is caused by
effects on both IRS-1 and IRS-2. In the case of IRS-1, the
effects appear to be partially mediated by S6K, with both
S6K1 and S6K2 contributing to reduced insulin signaling.
IRS-1 is a novel substrate for S6K
We reasoned that IRS-1 may also be a novel substrate for S6
kinases, and tested the ability of GST-tagged IRS-1 frag-
Figure 4. Inhibition of S6K restores insulin signaling. (A) Treatment of IRS-1 immunopre-
cipitates with  -phosphatase indicating that reduced migration of IRS-1 in TSC2
 /  MEFs is 
due to increased phosphorylation. (B) Treatment of serum-starved TSC2
 /  or TSC2
 /  MEFs 
for various times with rapamycin followed by immunoblotting for IRS-1 (top) or IRS-2 (bot-
tom). The slower migrating, more heavily phosphorylated IRS-1 or IRS-2 present in TSC2
 /  
MEFs is indicated with an arrow; the faster migrating IRS-1 or IRS-2 present in TSC2
 /  cells 
or after rapamycin treatment is indicated with an arrowhead. (C) PKB activation by insulin 
or IGF-1 after treatment of TSC2
 /  or TSC2
 /  MEFs with rapamycin for the indicated times. 
Top, Ser473-phosphorylated PKB; bottom, level of total PKB. (D) PIP3 levels in TSC2
 /  
(gray bars) or TSC2
 /  (white bars) MEFs after IGF-1 stimulation in untreated cells or cells 
pretreated for 24 h with 20 nM rapamycin. Results from triplicate determinations (means and 
SDs) are shown normalized to control unstimulated samples and are representative of three 
independent experiments. (E) PKB activation after RNAi-mediated inhibition of IRS-1, IRS-2, 
IRS-1 plus IRS-2, or a combination of scrambled IRS-1 and IRS-2 siRNA (Scrambled) in TSC2
 /  
MEFs stimulated by insulin for 10 min after treatment with 20 nM rapamycin for 1 h. First 
panel, IRS-1; second panel, IRS-2; third panel, Ser473-phosphorylated PKB; bottom panel, 
total PKB. (F) Rescue of PKB activation in TSC2
 /  MEFs after overexpression of IRS-1 or IRS-2. 
Extracts from mock-transfected TSC2
 /  MEFs (C) or MEFs transfected with expression constructs expressing myc-IRS-1 or IRS-2 were starved 
for 24 h after transfection and were treated with 20 nM rapamycin for 1 h before stimulation with insulin for 10 min. Where indicated, mock-
transfected cells were also treated with 20 nM rapamycin for 24 h before stimulation. First panel, myc-IRS-1 detected with 9E10 monoclonal; 
second panel, IRS-2; third panel, Ser473-phosphorylated PKB; bottom panel, total PKB. (G) PKB activation in TSC2
 /  MEFs after RNAi-mediated 
inhibition of S6K1, S6K2, S6K1 plus S6K2, or a mixture of S6K1 and S6K2 scrambled siRNAs (Scrambled) after insulin stimulation for 10 min. 
Scrambled siRNA-transfected cells were also treated with 20 nM rapamycin for 24 h before insulin stimulation where indicated.TSC1-2 controls insulin signaling by suppressing S6K | Harrington et al. 217
ments covering the entirety of the protein to be phosphory-
lated in vitro by S6K, in comparison to S6. A fragment en-
compassing residues 108–516 (IRS-1
108–516) is efficiently
phosphorylated by S6K in vitro (Fig. 5 B). Comparison of
the S6K phosphorylation site in S6 with IRS-1
108–516 reveals
three potential phosphorylation sites in which an RxRxxS is
followed by distal serines as occurs in S6 (Fig. 5 A). We mu-
tagenized both the proximal (RxRxxS) and distal serines in
each of these potential sites and asked whether such mutants
could be phosphorylated in vitro. The results show that only
in IRS-1
108–516 in which serines 302, 307, and 310 are mu-
tated (Fig. 5 A, site 2) is IRS-1 not phosphorylated in vitro
by S6K1 (Fig. 5 C, left panels). Individual mutagenesis of
serines 307 and 310 has little effect on IRS-1
108–516 phos-
phorylation, indicating that this site is not phosphorylated at
multiple serines like that of S6, whereas mutagenesis of
serine 302 to alanine ablates phosphorylation (Fig. 5 C,
right panels). This result was confirmed using Western blot-
ting with a phospho-Ser302 antibody that only recognizes
wild-type IRS-1 after in vitro phosphorylation by S6K (Fig.
5 D). To confirm that this phosphorylation detected in vitro
is sensitive to TSC2 in vivo, we probed extracts with this an-
tibody. Although the level of IRS-1 is reduced in TSC2-defi-
cient MEFs compared with TSC2-expressing MEFs (Fig. 2
C and Fig. 5 E), the level of Ser302-phosphorylated IRS-1 is
greatly increased (Fig. 5 E) and rapamycin sensitive (Fig. 5
F). We again used S6K siRNAs to determine whether IRS-1
Ser302 phosphorylation is through S6K in vivo. The result
indicates that IRS-1 Ser302 phosphorylation is decreased af-
ter siRNA-mediated suppression of S6K1, but is unaffected
by suppression of S6K2 (Fig. 5 G). Thus, in TSC2
 /  MEFs
cells, IRS-1 Ser302 phosphorylation is regulated primarily
by S6K1, and not S6K2, although the less effective knock-
down of S6K2 expression leaves open the formal possibility
of some contribution from this kinase also.
Phosphorylation by S6K inhibits IRS-1 function
Next, we asked whether IRS-1 could be tyrosine phosphory-
lated and associate with PI3K in TSC2
 /  MEFs after stim-
ulation with insulin. The results show that in TSC2
 / 
MEFs, IRS-1 is both poorly tyrosine phosphorylated and as-
sociated with PI3K after stimulation of cells with insulin.
Rapamycin treatment for 1 h results in a partial restoration
of both IRS-1 tyrosine phosphorylation and association with
the p85 subunit of PI3K in TSC2
 /  MEFs (Fig. 6, A and
B). Importantly, this short-term treatment does not signifi-
cantly alter IRS-1 protein levels (Fig. 4, B and E), which ar-
gues that the reduction in signaling capacity is attributable
Figure 5. IRS-1 is a novel S6K substrate. (A) Domain structure of IRS-1 indicating regions of 
GST fusions (aa numbering based on murine IRS-1) used for in vitro kinase assays and comparison 
of the S6 phosphorylation site with candidate S6-like phosphorylation sites present in IRS-1
108–516. 
Conserved arginines are shown in bold, serines phosphorylated by S6K in S6 and potentially 
phosphorylated in IRS-1
108–516 are shown in red, and serines mutated to alanines in mutants of 
sites 1–3 are underlined. Also shown is the homologous site to site 2 in murine IRS-2. (B) In vitro 
kinase assay of GST-IRS-1 fragments with purified S6K2. Full-length GST fusion proteins (1–4, as 
indicated in A) and 40S ribosomal proteins containing S6 (40S) in these preparations are indicated 
with asterisks in the Coomassie blue–stained gel (right), and the 
32P-labeled proteins after the kinase assay and autoradiography are shown on 
the left. Two phosphorylated bands are noted in kinase assay with IRS-1
108–516, the lower of which represents a poorly resolved doublet of 
cleaved forms of the protein. An arrow indicates 
32P-labeled S6 present in the 40S ribosome preparation. (C) In vitro kinase assay of IRS-1 
site-directed mutants by S6K1. Top panels, autoradiographs; bottom panels, Coomassie blue–stained gels; left panels, phosphorylation of 
IRS-1
108–516 (WT) and site 1–3 compound mutants as indicated in Fig. 4 A; right panels, phosphorylation of IRS-1
108–516 and individual serine-
to-alanine mutants of the serine residues within site 2. (D) Ser302 phosphorylation of IRS-1
108–516 wild-type (WT) or IRS-1
108–516 with Ser302 
mutated to alanine (S302A) detected with a phosphospecific antibody to IRS-1 Ser302 after in vitro phosphorylation by S6K1. (E) IRS-1 Ser302 
phosphorylation is elevated in vivo. Top, Ser302-phosphorylated IRS-1 detected by a phosphospecific Ser302 antibody in extracts from 
serum-starved isogenic TSC2
 /  and TSC2
 /  MEFs, and TSC2
 /  MEFs lines in which wild-type ( /  ( WT)) or a pathogenic mutant TSC2 
( /  ( N1643K)) has been reintroduced; top, Ser302-phosphorylated IRS-1; bottom, total IRS-1. (F) IRS-1 Ser302 phosphorylation is inhibited 
by mTOR/S6K inhibition with rapamycin in serum-starved TSC2
 /  MEFs. Top, Ser302-phosphorylated IRS-1; bottom, total IRS-1. Where 
indicated, MEFs were also stimulated with insulin for 10 min. (G) IRS-1 Ser302 phosphorylation is diminished in TSC2
 /  MEFs after siRNA-
mediated inhibition of S6K1. Top, Ser302-phosphorylated IRS-1; bottom, total IRS-1. Where indicated, MEFs were also stimulated with 
insulin for 10 min.218 The Journal of Cell Biology | Volume 166, Number 2, 2004
to impaired function as well as a reduction in the pool of
available IRS-1. Sustained inhibition of S6K signaling by ra-
pamycin treatment of TSC2
 /  MEFs restores both tyrosine
phosphorylation and PI3K association to levels approaching
that of TSC2
 /  cells (Fig. 6 A). Then, we asked whether
phosphorylation of IRS-1
108–516 by S6K directly inhibits its
association with activated insulin receptors. We phosphory-
lated in vitro a GST fusion protein containing the phospho-
tyrosine-binding domain (PTB) of IRS-1 with S6K, and
determined the amount of activated insulin receptor that as-
sociated with unphosphorylated or phosphorylated IRS-1 in
a pull-down assay. The result shows that phosphorylation of
the IRS-1 PTB domain by S6K markedly decreases its as-
sociation with insulin receptor (Fig. 6, C and D), whereas a
Ser302-glutamic acid mutant, which may mimic the effect
of phosphorylation at this site, exhibits impaired binding to
the insulin receptor (Fig. 6, E and F). Thus, S6 kinases di-
rectly phosphorylate IRS-1 at Ser302, and the resulting re-
duction of binding to insulin receptors is likely to play a ma-
jor role in the inability of IRS-1 to signal to PI3K.
Impaired PI3K signaling abrogates IGF-1–mediated 
chemotaxis and survival
PI3K activation by insulin or IGF-1 is required for migra-
tion/chemotaxis and survival. Survival is known to involve
activation of PKB (Lawlor and Alessi, 2001), whereas che-
motaxis requires PI3K activity (Puglianiello et al., 2000).
Therefore, we tested the responses of TSC2
 /  or TSC2
 / 
MEFs to IGF-1 in chemotaxis and survival assays. We ob-
serve a similar basal and EGF-stimulated rate of migration
for both TSC2 genotypes, but a pronounced impairment in
IGF-1–stimulated chemotaxis in TSC2
 /  MEFs. Pretreat-
ment with rapamycin for 24 h has little effect on migration
of TSC2
 /  MEFs, but restores IGF-stimulated migration of
TSC2
 /  MEFs (Fig. 7, A and B).
Next, we tested the ability of IGF-1 to act as a survival fac-
tor for TSC2
 /  or TSC2
 /  cells. We assessed survival after
serum removal, an assay in which IGF-1 is known to act as a
survival factor (Tamm and Kikuchi, 1990). IGF-1 signifi-
cantly protects TSC2
 /  MEFs from apoptosis, but has little
protective effect on TSC2
 /  cells (Fig. 7). TSC2
 /  MEFs
exhibit a higher basal rate of survival in the absence of se-
rum, raising the possibility that additional pro-survival path-
ways may be activated in these cells. Because rapamycin has
been shown to lead to increased apoptosis of TSC2-deficient
tumor cells in vivo (Kenerson et al., 2002) and S6K1 phos-
phorylation has been implicated in inactivation of the pro-
apoptotic factor Bad (Harada et al., 2001), we assessed basal
and IGF-1–mediated survival after treatment of cells with
rapamycin. The results show that rapamycin treatment has
Figure 6. S6K phosphorylation blocks 
IRS-1 function. (A) IRS-1 tyrosine phos-
phorylation and association with PI3K is 
suppressed in TSC2
 /  MEFs and rescued 
by inhibition of S6K. IRS-1 immunopre-
cipitates in unstimulated or insulin-stimu-
lated TSC2
 /  or TSC2
 /  MEFs after 
rapamycin treatment for the indicated 
times, immunoblotted for phosphotyrosine 
(panel 1), or the coimmunoprecipitation 
of the p85 subunit of PI3K (panel 2). The 
total levels of IRS-1 and p85 in cell lysates 
are indicated in panels 3 and 4, respec-
tively. (B) Quantitation of insulin-
stimulated IRS-1 tyrosine phosphorylation 
in untreated TSC2
 /  MEFs or the same 
cells after rapamycin treatment for the 
indicated times. An arbitrary value was 
obtained representing the difference 
between unstimulated and the corre-
sponding insulin-stimulated level of phos-
photyrosine in IRS-1 immunoprecipitations 
as detected on scanned autoradiographs. The values from three independent exper-
iments were averaged and plotted on a bar chart, with the error bars showing the 
SEM. (C) Phosphorylation of immobilized GST-IRS-1
108–516 PTB domain by S6K2 
inhibits insulin receptor (InR) interaction. The interaction with tyrosine-phosphory-
lated InR (top) was determined in vitro by the addition of glutathione beads 
containing the indicated amounts of S6K2-phosphorylated or unphosphorylated 
GST-IRS-1
108–516 or GST to lysates prepared from insulin-stimulated CHO-IR cells. 
An immunoblot of the level of GST-IRS-1 fusion protein or GST is indicated on the 
bottom. DP indicates degradation products of the GST-IRS-1 protein. (D) Quantita-
tion of InR binding to GST-IRS-1
108–516 (WT) or a mutant GST-IRS-1
108–516 in which 
serine 302 is mutated to alanine (S302A) after in vitro phosphorylation by S6K2. 
Error bars show the SEM from three experiments. (E) InR binding of wild-type GST-
IRS-1
108–516, or S302A and S302E mutants in a pull-down assay. Top, InR; bottom, 
anti-GST. (F) Quantitation of InR binding to GST-IRS-1
108–516 (WT) or S302A and 
S302E mutants. An arbitrary value of 100 was assigned for the binding of wild-type 
GST-IRS-1
108–516, and the binding of the mutant IRS-1 proteins was expressed relative 
to this value. Error bars show the SEM from three experiments.TSC1-2 controls insulin signaling by suppressing S6K | Harrington et al. 219
little effect on the survival of TSC2
 /  MEFs. However, ra-
pamycin has two effects on TSC2
 /  MEF survival, decreas-
ing basal survival in the absence of IGF-1 while increasing
survival in the presence of IGF-1 (Fig. 7, C and D). We con-
clude that under the conditions of serum withdrawal, IGF-1
does not activate pro-survival signaling in TSC2-deficient
cells, and that a weaker pro-survival signal is instead pro-
vided by mTOR/S6K signaling.
Discussion
The insulin–PI3K pathway controls cell number (through
promoting cell cycle progression and survival via PKB/AKT;
Lawlor and Alessi, 2001) and cell growth (via activation of
the S6Ks; Dufner and Thomas, 1999). How, then, do cells
and tissues coordinate these activities, given that different
relative amounts of cells and growth may normally be re-
quired to obtain a given organ size, or to modulate this size
during development or in the adult? Regulators of coordina-
tion may be inferred from human pathologic overgrowth
conditions in which such coordination is lost, or in model
organisms such as Drosophila where loss-of-function muta-
tions can be analyzed for their effect on organ growth. Both
PTEN (Nelen et al., 1997) and TSC1-2 (mutated in TSC;
The European Chromosome 16 Tuberous Sclerosis Consor-
tium, 1993; van Slegtenhorst et al., 1997) may play coordi-
nating roles in organ size control (Goberdhan et al., 1999;
Tapon et al., 2001). However, PTEN (but not thus far
TSC1-2) mutations are known to promote tumorigenesis,
with the gene frequently mutated or lost in advanced neo-
plasms (Li et al., 1997). A connection between PTEN and
TSC1-2 has also been proposed via PTEN loss of function
leading to hyperactivation of the protein kinase PKB/AKT,
which phosphorylates tuberin (Inoki et al., 2002; Manning
et al., 2002). Tuberin phosphorylation has been suggested to
negatively regulate the TSC1-2 protein complex, allowing
activation of S6K and cell growth (Potter et al., 2002).
In this paper, we have explored the failure of insulin to ac-
tivate PKB in TSC2
 /  cells (Jaeschke et al., 2002). How-
ever, the absence of TSC1-2 complex function leads not to a
specific failure in PKB activation, but rather to a general failure
in insulin’s ability to activate PI3K. As a result of TSC1-2
loss of function, insulin-like growth factors do not activate
PI3K due to S6K inactivating the adaptor proteins IRS-1
and IRS-2. S6K activation appears to attenuate PI3K signal-
ing through suppressing the adaptor protein IRS-1, both at
the level of gene transcription and at the level of its function
in coupling activated receptors to PI3K. The former mecha-
nism is unexpected, and is mediated by S6K1 and S6K2, in-
dicating that these protein kinases have a direct role in regu-
lating IRS-1 transcription. A transcription factor, CREM,
has already been shown to be a substrate for S6K1 (de Groot
et al., 1994).
Although the full range of consequences of activation of
the mTOR/S6K pathway remain to be determined, it ap-
pears that a reduced responsiveness to growth factors may
not be restricted to insulin signaling (H. Zhang et al., 2003).
Future experiments will help clarify whether such “indirect”
inhibitory consequences of aberrant mTOR/S6K activation
on cell signaling play a role in the distinctive pathology of
hamartoma development in TSC.
A second major mechanism of IRS-1 inactivation by S6K
is through phosphorylation. We have identified a site
(Ser302) proximal to the IRS-1 PTB domain that we show
Figure 7. IGF-1–mediated migration and 
survival are impaired in TSC2-deficient MEFs. 
(A) A chemotaxis assay indicating the migration 
of TSC2
 /  or TSC2
 /  MEFs in the absence or 
presence of 50 ng/ml IGF-1 or 20 ng/ml EGF as a 
chemotactic factor in a Transwell assay. The 
pictures show fluorescently labeled cells that 
have traversed a fluorescently inert filter, such 
that only the cells that have crossed the filter are 
photographed. Basal migration (left-hand panels) 
in the presence of 0.5% FCS present in both 
chambers and IGF-1–stimulated migration (mid-
dle panels) or EGF-stimulated migration (right-
most two panels) is shown in untreated cells (top 
six panels) or cells pretreated with 20 nM rapa-
mycin for 24 h (bottom four panels). (B) Quan-
titation of IGF-1– or EGF-mediated chemotaxis 
in the chemotaxis assay of TSC2
 /  (gray bars) or TSC2
 /  (white bars) 
MEFs. The results are expressed as a percentage of that of IGF-1–stimu-
lated chemotaxis of TSC2
 /  MEFs not treated with rapamycin (100%) 
from four random 10  fields of two duplicate wells. Error bars show 
the SEM values. (C) Cell survival assay in the absence of serum. A 
quantitative analysis of the percentage of TUNEL-positive nuclei is 
shown for TSC2
 /  (gray bars) and TSC2
 /  (white bars) MEFs after 8 h 
in serum-free medium alone ( ) or supplemented with 200 ng/ml 
IGF-1 ( ) in untreated MEFs or MEFs pretreated for 36 h with 20 nM 
rapamycin. The results are from four random 10  fields and are typical 
of experiments performed twice. (D) Relative cell survival of TSC2
 /  
(gray bars) or TSC2
 /  (white bars) MEFs. The results were obtained by 
dividing the means of the percentages of TUNEL-positive nuclei in the 
absence of IGF-1 by the means of those in the presence of IGF-1.220 The Journal of Cell Biology | Volume 166, Number 2, 2004
is phosphorylated by S6K in vitro, which shows increased
phosphorylation in TSC2-deficient cells and is sensitive to
inhibition of mTOR/S6K signaling. Our data indicate that,
at least in TSC2
 /  MEFs, the major kinase responsible for
phosphorylating IRS-1 Ser302 is S6K1 and that phosphory-
lation of this site may disrupt the ability of the PTB domain
to interact with activated insulin receptors. Reversal of this
phosphorylation by short-term treatment with rapamycin,
or inhibition of S6K1 by RNAi, partially rescues activation
of PKB, arguing that phosphorylation by S6K may be a ma-
jor mechanism to inactivate IRS-1 function. However, the
extent of the band shift we observe in both IRS-1 and IRS-2
extracted from TSC2-deficient cells might suggest that more
than one site is phosphorylated by S6K (or perhaps other
mTOR-regulated kinases) in vivo; our data support the ar-
gument that the direct phosphorylation of the PTB domain
site could account for the profound inhibition of IRS-1
function in these cells. Giraud et al. (2004) have also re-
ported that IRS-1 is phosphorylated at Ser302, by an uni-
dentified nutrient- and rapamycin-sensitive kinase. How-
ever, using a Ser302-alanine mutant in 32D cells, these
workers report that Ser302 phosphorylation may be neces-
sary for association with PI3K p85 and for a restricted set
of insulin–PI3K-regulated responses including activation of
S6K and DNA synthesis. Surprisingly, their work indicates
that activation of PKB is largely unaffected by preventing
phosphorylation at this site, suggesting that PIP3 generation
is unaffected by preventing Ser302 phosphorylation. How-
ever, they did not examine the consequences upon insulin
signaling of a phosphomimic of Ser302 (which may reflect
the situation occurring upon activation of mTOR/S6K sig-
naling reported here), rendering it difficult to determine
what the consequences of increased phosphorylation of this
site may be. However, our finding that regulation of IRS by
S6K occurs by both long-term (transcriptional) and acute
(phosphorylation) mechanisms, and that both these mecha-
nisms act in the same manner (i.e., inhibitory) toward insu-
lin–PI3K activation, is consistent with what we observe in
TSC2
 /  cells where S6K is hyperactive and PI3K activation
is defective. We suggest that TSC1-2, S6K, and S6K-regu-
lated inactivation of IRS proteins is a negative feedback sen-
sor that may be designed to relate the amount of nutrient/
S6K-dependent growth to the magnitude of insulin’s activa-
tion of PI3K.
The contribution of unregulated S6K activity to tumori-
genesis is currently unknown. Some TSC1-2–deficient le-
sions have increased levels of phosphorylated S6, indicating
elevation of S6K activity (Kwiatkowski et al., 2002; Kar-
bowniczek et al., 2003). Treatment of Eker rat tumors, in
which TSC2 is inactivated, with the mTOR inhibitor rapa-
mycin leads to increased apoptosis of these cells, indicating that
mTOR/S6K signaling may be important here (Kenerson et
al., 2002). However, it is also clear that mice rendered TSC-
null by genetic means do not develop beyond mid-gestation
(Kwiatkowski et al., 2002), whereas in TSC, hamartomatous
growths are generally slow or normally growing, and have a
low malignant potential. This contrasts with PTEN inactiva-
tion in Cowden disease, in which predisposition to malig-
nancy is evident (Starink et al., 1986). Our model (Fig. 8)
suggests that an explanation for the low level of malignancy
observed in TSC1-2–deficient tumors may be that insuffi-
cient pro-tumorigenic PIP3-dependent signals (such as PKB
activation) are generated in TSC1-2–deficient tumor cells,
and that such signals may be required for malignant conver-
sion. Our data also suggest a paradigm of how appropriate or-
gan size control may be achieved: cell growth through S6 ki-
nases may be either coordinated with PI3K-regulated cell
number control or uncoupled from it, depending on the
presence or absence of a functional TSC1-2 complex.
Materials and methods
Antibodies
Commercial antibodies used were as follows: rabbit anti-GST, anti-p85,
anti-IRS-1, and mouse anti-phosphotyrosine (clone 4G10) were from Up-
state Biotechnology. Anti-PKB, IGF-1R, pS6 (Ser240/244), PKB Ser473,
and total GSK3 /  and GSK3 /  Ser21/9 were from Cell Signaling. Anti-
bodies to ERK1/2 and S6K1 were from Santa Cruz Biotechnology, Inc., and
Transduction Laboratories, respectively. An anti-InR mAb CT3 was from K.
Siddle (University of Cambridge, Cambridge, UK), and an antibody to
Figure 8. A model for TSC1-2 regulation of insulin 
signaling to PI3K. The elevated production of the 
inositol phospholipid PIP3 by PI3K and its antag-
onism by PTEN (and 5-phosphatases; not depicted) 
determines the activation of downstream responses 
such as activation of PKB. A further downstream 
response to PKB activation may be the inactivation 
of TSC1-2 via phosphorylation of tuberin, resulting 
in S6K activation. In our model, TSC1-2 promotes 
insulin-like growth factor signaling to PI3K by re-
pressing a negative feedback loop from mTOR/S6K 
to the adaptor molecule IRS-1. This negative regu-
lation by TSC1-2 may be on mTOR effectors 
(Jaeschke et al., 2002) or on mTOR directly (Tee et 
al., 2002). A similar negative feedback involving 
S6K repression of PKB activation has also been 
described in Drosophila (Radimerski et al., 2002), 
although the target of dS6K’s inhibitory action here 
is not known. Repression of IRS-1 by mTOR/S6K 
occurs via both a transcriptional repression of IRS-1 
gene expression mediated by both S6K1 and S6K2 and by direct phosphorylation of IRS-1 protein close to the PTB domain by S6K1. Therefore, 
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S6K2 was from D. Alessi (University of Dundee, Dundee, UK). Antibodies
to IRS-2 and IRS-1 phosphorylated at Ser302 were gifts from M. White (Jos-
lin Diabetes Center, Boston, MA).
Cell culture, treatments with growth factors, and
siRNA transfections
Starved MEFs (Jaeschke et al., 2002) were stimulated with 1  g/ml insulin,
50 ng/ml IGF-I, or 20 ng/ml EGF for 10 min. CHO-IR cells were main-
tained in Ham’s F12 medium with 10% FCS and were starved in medium
lacking serum for 24 h. To activate insulin receptors, cells were then stim-
ulated for 10 min with 1  M insulin. siRNAs (Dharmacon) for S6K were:
S6K1, 5 -GGACATGGCAGGAGTGTTT-3 ; and S6K2, 5 -GAACCAAG-
AAGTCCAAGAA-3 .
For IRS-1 and IRS-1/IRS-2 double transfections, the sequences used
were as described previously (Pirola et al., 2003). For IRS-2 single transfec-
tion, the following sequence was used: IRS-2, 5 -CCAAGCACAAGTACCT-
GAT-3 .
SiRNAs were transfected using LipofectAMINE™ 2000 and cells were
harvested after 24 h (for IRS-1 and IRS-2) or 5 d (S6K1 and S6K2).
PI3K assay and PIP3 determination
Assays were performed as described previously (Herbert et al., 2000) and
were imaged using a PhosphorImager (Fuji); bands were quantified using
AIDA analysis software. Results were expressed as histograms in Microsoft
Excel. Estimation of PIP3 was by a TRFRET displacement assay (Gray et al.,
2003). The estimates of PIP3 were normalized to total lipid extracted as
described previously (Raheja et al., 1973).
RNA analysis
Murine gene oligo microarray slides ( 7.5k genes/slide) were obtained
from the Human Mapping Project (Cambridge, UK). Fluorescently labeled
cDNA probes were prepared using the Atlas™ Glass Fluorescent Labeling
Kit (CLONTECH Laboratories, Inc.) and Cy3 and Cy5 reactive dyes (Amer-
sham Biosciences), and were processed according to the manufacturer’s
instructions. For Northern blotting, RNA was run on agarose-formaldehyde
gels, blotted onto Hybond™-N, and hybridized and washed using stan-
dard procedures. Two-step quantitative RT-PCR was performed using
cDNA synthesized using the Omniscript™ RT Kit (QIAGEN) using total
RNA purified from appropriately treated MEFs using the RNeasy™ Mini Kit
(QIAGEN). For the actinomycin D experiment, TSC2
 /  cells were starved
for 24 h in the absence or presence of 20 nM rapamycin or for 24 h with
rapamycin with addition of 10  g/ml actinomycin D for the last 10 h.
Quantitative PCR was performed using the JOE-labeled mouse  -actin
LUX™ Primer set (Invitrogen) and an IRS-1–specific primer pair with a
6-FAM–labeled probe synthesized by QIAGEN. Reactions were performed
using the PCR Master Mix for probe assays (Eurogentech) with  -actin
LUX™ primers at a final concentration of 200 nM, the IRS-1 primers at a fi-
nal concentration of 300 nM, and the probe at 100 nM. Reactions were
performed in triplicate using a sequence detector (ABI Prism™ 7700; Ap-
plied Biosystems). Results were analyzed using Sequence Detector v1.7
software.
Immunoprecipitations
Cells were lysed in buffer (50 mM Tris-HCl, pH 7.5, 120 mM NaCl, 1%
NP-40, 1 mM EDTA, 50 mM NaF, 40 mM  -glycerolphosphate, 5 mM
Na3VO4, 1  g/ml leupeptin, 1  g/ml aprotinin, and 1 mM benzamidine).
300  g protein was added to 2  g anti-IRS-1 antibody and immunoprecip-
itations were performed for 12 h at 4 C, followed by a further 2-h rotation
after addition of 10  l protein G–agarose and washing. For  -phosphatase
experiments, washed immunoprecipitates were washed with  -phos-
phatase reaction buffer (50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 2 mM
MnCl2, 0.1 mM EDTA, and 5 mM DTT) and resuspended in 15  l of this
buffer with or without 400 U purified  -phosphatase, and reactions were
incubated at 30 C for 1 h with regular agitation.
Protein methods
GST-IRS-1 (aa 21–400, 108–516, 516–895, and 895–1235) were eluted
from glutathione-agarose beads in 50 mM Tris-HCl, pH 8.0, and 10 mM
glutathione, dialyzed against 50 mM Tris-HCl, pH 8.5, 150 mM NaCl,
10% glycerol, 1 mM PMSF, 1 mM benzamidine, and 1 mM DTT, and were
concentrated. Recombinant EE-S6K1 and EE-S6K2 were purified from in-
sect cells infected with generated viruses using mouse EE mAb immobi-
lized to protein A–Sepharose CL-4B (Amersham Biosciences). In vitro ki-
nase assays were performed in kinase assay buffer (50 mM Tris-HCl, pH
7.5, 10 mM MgCl2, 50  M cold ATP, 5  Ci  [
32P]-labeled ATP) using ei-
ther 1  g GST-IRS-1 fragments or 0.4  l 40S ribosomal preparation as a
substrate (Gout et al., 1998). Reactions were at 30 C for 20 min.
For the InR-binding assay, phosphorylation of GST-IRS-1 was per-
formed for 30 min at 37 C in 15  l kinase reaction buffer with 200  M
cold ATP and 0.6  g S6K2. Proteins were bound to glutathione-agarose
and washed twice with kinase buffer and once with lysis buffer A (50
mM Tris-Cl, pH 7.4, 150 mM NaCl, 50 mM NaF, 1 mM benzamidine, 1
mM EDTA, 1% NP-40, 40 mM  -glycerophosphate, 5 mM sodium ortho-
vanadate, 2 mM PMSF, 1  g/ml leupeptin, 1  g/ml aprotinin, and 10%
glycerol). CHO cells overexpressing IR were lysed in buffer A, and 0.5
mg protein was used for the binding assay performed at 4 C for 1 h, fol-
lowed by three washes with A buffer, addition of SDS-PAGE sample
buffer, and SDS-PAGE. Mutants of GST-IRS-1 (aa 108–516) were pro-
duced using the QuikChange
® Site-Directed Mutagenesis Kit (Strat-
agene). For the quantitation and statistical analysis of InR pull-down, au-
toradiographs were scanned and the pixel intensity of bands was
determined using Adobe Photoshop
® and corrected for background pixel
intensity. Insulin receptor associated with GST-IRS-1 wild-type and GST-
IRS-1 S302A in each control experiment (i.e., without kinase) was as-
signed a value of 100%. Insulin receptor associated with GST-IRS-1 wild
type and GST-IRS-1 S302A after phosphorylation by S6K was normalized
relative to the control value of 100% in each experiment. Values from
three independent experiments were analyzed, and the average value
was plotted on the graph.
Cell chemotaxis assay
MEFs were starved for 24 h in the presence or absence of 20 nM rapamy-
cin and were labeled 1 h further with 2  g/ml CellTracker™ Green (Mo-
lecular Probes, Inc.) before trypsinization. 20,000 cells were plated in du-
plicate on Fluoro-block Transwell filters (Becton Dickinson) in DME
containing 0.5% FCS, and were placed in wells containing the same media
or media containing 50 ng/ml recombinant IGF-1 or 20 ng/ml recombinant
EGF (Sigma-Aldrich). Chemotaxis was for 6 h, after which the wells were
fixed in PBS/4% PFA. Fluorescence was visualized in 10  fields using
FITC excitation/emission on an upright microscope (DM-IRB; Leica)
equipped with a digital camera (CoolSnap) and Darkroom image acquisi-
tion software (Improvision). For quantitation, three random fields were im-
aged from each duplicate assay and the number of spread fluorescent cells
that had crossed the filter was counted manually. Cell numbers were ex-
pressed as a percentage of that of TSC2
 /  in the presence of IGF-1, and a
histogram was generated in Microsoft Excel.
Cell survival assay
20,000 cells were seeded in duplicate onto coverslips in the absence or
presence of 20 nM rapamycin. After 36 h, coverslips were washed twice in
PBS and placed in wells containing serum-free DME in the presence or ab-
sence of 200 ng/ml IGF-1 for 8 h. Cells were fixed in 4% PFA, permeabi-
lized, and subjected to FITC-TUNEL assay using a commercial kit (Apopto-
sis Detection System; Promega) with the addition of a 30-min labeling
stage with 1  g/ml Hoechst bisbenzamide to label cell nuclei. In each du-
plicate assay, two 10  fields containing 300–600 nuclei were imaged
with DAPI and FITC excitation/emission on a microscope (Axioplan 2; Carl
Zeiss MicroImaging, Inc.) with an Axioplan camera and software. In each
field, the number of TUNEL-positive nuclei and nuclei for each condition
was counted manually and expressed as a percentage and a histogram
generated in Microsoft Excel.
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